HSD17B12 and neuroblastoma: Our analysis revealed that high HSD17B12 expression is significantly associated with adverse clinical indicators, such as stage 4 disease (Stage 4 versus Stage 1: p‐value = 3 × 10−5), MYCN amplification (p‐value = 4.14 × 10−7), and classification within the high‐risk neuroblastoma group (p‐value = 3.25 × 10−11) (Figure S7A–C, Supporting Information).